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Key Clinical Message
Sezary syndrome is an extremely rare form of cutaneous T-cell lymphoma. It
presents suddenly and is associated with a poor prognosis. Clinical recognition
is crucial for the diagnostic process and initiation of appropriate treatment.
Plantar keratoderma is usually pathognomonic for Sezary syndrome and clini-
cians should be alerted to its presence.
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A 65-year-old woman presented with a 4-year history of
progressive refractory diffuse pruritus. She had been diag-
nosed 4 months earlier with cutaneous T-cell lymphoma
(CTCL) stage I (mycosis fungoides). After being treated
unsuccessfully with PUVA for 31 sessions, she was even-
tually diagnosed with CTCL stage IVA2 (Sezary syn-
drome) on the basis of severe worsening pruritus,
erythroderma, palmoplantar keratoderma with skin
ulcerations causing cellulitis (Fig. 1A), left eye ectropion,
lymphanedopathy, positive skin biopsy and left inguinal
lymph node biopsy, raised lactate dehydrogenase, Sezary
cells over 1000/lL with positive clonality, CD4/CD8 ratio:
12.5, and CT chest, abdomen and pelvis showing inguinal
and axillary lymphadenopathy with no visceral involve-
ment. With bexarotene, interferon-alfa, and extracorpo-
real photopheresis, her keratoderma stabilized (Fig. 1B),
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Figure 1. Plantar Keratoderma at the time of diagnosis (A) and after 1 month of treatment (B).
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and after 2 months of treatment with keratolytics (6%
salicylic acid in 70% propylene glycol and clobetasol), it
largely cleared.
Sezary syndrome is CTCL stage IV and its incidence
is 1 in 10,000,000 with predicted median survival
between 2 and 4 years [1, 2]. Its skin changes are char-
acteristic and clinicians should be alarmed to severe pru-
ritus with keratoderma as to exclude lymphoma. Despite
the possibility to use first-line agents as treatment, allo-
genic stem cell transplantation is considered the only
curative approach.
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